News

SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG

SpeeDx announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus MG.

“This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium – a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine.

Read the full press release